Abstract

Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial
Valentin Goede ...
Blood | VOL. 134
Valentin Goede, et. al.Valentin Goede ...
13 Nov 2019
Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial
Carsten Utoft Niemann ...
Blood | VOL. 134
Carsten Utoft Niemann, et. al.Carsten Utoft Niemann ...
13 Nov 2019
Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
Peter Hillmen ... Talha Munir
Blood | VOL. 132
Peter Hillmen, et. al.Peter Hillmen ... Talha Munir
29 Nov 2018
Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial, a Mantle Cell Lymphoma Network Study
Marie-Helene Delfau ... Vincent Ribrag
Blood | VOL. 138
Marie-Helene Delfau, et. al.Marie-Helene Delfau ... Vincent Ribrag
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results.
Joseph A Pidala ... Brian C Betts
Blood | VOL. -
Joseph A Pidala, et. al.Joseph A Pidala ... Brian C Betts
24 Jul 2024
Critical Role of Tripartite Fusion and LBD Truncation in Certain RARA- and all RARG-Related Atypical APL.
Xiaosu Zhou ... Hongxing Liu
Blood | VOL. -
Xiaosu Zhou, et. al.Xiaosu Zhou ... Hongxing Liu
24 Jul 2024
Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4).
Franco Locatelli ... Christina Diaz-De-Heredia
Blood | VOL. -
Franco Locatelli, et. al.Franco Locatelli ... Christina Diaz-De-Heredia
24 Jul 2024
A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.
Xiaoshuai Zhang ... Qian Jiang
Blood | VOL. -
Xiaoshuai Zhang, et. al.Xiaoshuai Zhang ... Qian Jiang
24 Jul 2024
View more papers